Exelixis (NASDAQ:EXEL) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Friday.
A number of other brokerages have also weighed in on EXEL. SunTrust Banks restated a “buy” rating and set a $38.00 price objective on shares of Exelixis in a research note on Thursday, December 21st. Zacks Investment Research raised Exelixis from a “hold” rating to a “buy” rating and set a $29.00 target price on the stock in a report on Tuesday, October 10th. Needham & Company LLC increased their target price on Exelixis from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Tuesday, October 17th. Cann reaffirmed a “hold” rating on shares of Exelixis in a report on Thursday, January 4th. Finally, Oppenheimer reaffirmed a “hold” rating on shares of Exelixis in a report on Monday, October 16th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Exelixis has a consensus rating of “Buy” and a consensus target price of $32.13.
Shares of Exelixis (NASDAQ:EXEL) opened at $28.00 on Friday. The company has a market capitalization of $8,283.88, a PE ratio of 54.90, a price-to-earnings-growth ratio of 0.84 and a beta of 1.88. Exelixis has a 12 month low of $16.72 and a 12 month high of $32.50.
Exelixis (NASDAQ:EXEL) last posted its earnings results on Wednesday, November 1st. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.18. Exelixis had a return on equity of 105.47% and a net margin of 36.80%. The business had revenue of $152.50 million during the quarter, compared to analyst estimates of $104.91 million. During the same quarter last year, the firm earned ($0.04) earnings per share. The company’s revenue for the quarter was up 145.2% compared to the same quarter last year. research analysts forecast that Exelixis will post 0.49 EPS for the current fiscal year.
In other Exelixis news, Director Alan M. Garber sold 15,000 shares of Exelixis stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $30.30, for a total transaction of $454,500.00. Following the sale, the director now owns 64,829 shares of the company’s stock, valued at approximately $1,964,318.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 5.10% of the company’s stock.
Hedge funds have recently modified their holdings of the company. Mark Sheptoff Financial Planning LLC acquired a new position in shares of Exelixis in the 3rd quarter worth $120,000. Fisher Asset Management LLC acquired a new position in shares of Exelixis in the 3rd quarter worth $213,000. Caxton Associates LP acquired a new position in shares of Exelixis in the 2nd quarter worth $227,000. Private Advisor Group LLC acquired a new position in shares of Exelixis in the 2nd quarter worth $247,000. Finally, Raymond James Financial Services Advisors Inc. acquired a new position in shares of Exelixis in the 3rd quarter worth $236,000. Institutional investors own 80.84% of the company’s stock.
WARNING: This piece was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/21/exelixis-exel-stock-rating-lowered-by-bidaskclub.html.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.